⌘K
t
Omega Diagnostics Group PLC announced it received £4.0m in deferred consideration relating to the sale of its CD4 business. As of close of business on 24 November 2022, the company held cash balances of £6.5m.
| Date | 25 Nov 2022 |
| Time | 07:00:02 |
| Category | Miscellaneous |
| ID | 5537H |
OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
Receipt of deferred consideration
Omega (AIM: ODX), the specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition, announces that it has now received the £4.0m of deferred consideration relating to the sale of the CD4 business.
Accordingly, as of close of business on 24 November 2022, Omega held cash balances of £6.5m.
The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.
Contacts:
|
Omega Diagnostics Group PLC |
||
|
Jag Grewal, Chief Executive |
via Walbrook PR |
|
|
Chris Lea, Chief Financial Officer |
|
|
|
|
|
|
|
finnCap Ltd |
Tel: 020 7220 0500 |
|
|
Geoff Nash/Edward Whiley (Corporate Finance) |
|
|
|
Alice Lane/ Harriet Ward (ECM) |
|
|
|
|
|
|
|
Walbrook PR Limited |
Tel: 020 7933 8780 or omega@walbrookpr.com |
|
|
Paul McManus / Sam Allen |
Mob: 07980 541 893 / Mob: 07502 558 258 |
|
About Omega Diagnostics Group PLC
Omega (AIM: ODX) is a specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition.